Head to head
Setmelanotide against Bivamelagon
An injected MC4R agonist with FDA approval against an oral one with a 28 person phase 2 that completed in February 2026 with no results posted and no peer reviewed publication on the compound at all. Route of administration is the selling point; the evidence gap is the fact.
Column A
SetmelanotideSetmelanotide (MC4R agonist)
An FDA-approved MC4R agonist for rare genetic forms of obesity driven by defects in the melanocortin pathway.
Column B
BivamelagonBivamelagon (LB54640), oral melanocortin-4 receptor agonist
An oral MC4R agonist being developed as a tablet counterpart to injected setmelanotide. A 28 person phase 2 in hypothalamic obesity completed in February 2026 with no results posted, and there is no peer reviewed publication on the compound at all.
Side by side, on the facts we can check
| Attribute | Setmelanotide | Bivamelagon |
|---|---|---|
| Category | Melanocortin | Melanocortin |
| FDA status | FDA-approved (Imcivree) for specific genetic obesity indications | Not FDA approved. Investigational; phase 2 complete in hypothalamic obesity with no results posted, open label extension enrolling (September 2026). |
| Half-life | ~11 hours | Not reported |
| Molecular weight | 1,117.3 Da | Not reported |
| Mechanism | Selectively agonizes the melanocortin-4 receptor (MC4R) to restore satiety signaling disrupted by upstream genetic defects. | In human pharmacology of the class, MC4R activation in the hypothalamus reduces appetite; this is the pathway that loss of function mutations in POMC, PCSK1 and LEPR disrupt upstream of the receptor, and that setmelanotide restores. Bivamelagon is described by its developer as a selective MC4R agonist that is orally bioavailable. No receptor pharmacology, pharmacokinetics or dose response for bivamelagon has been published in a peer reviewed journal, so the mechanism on this page is inferred from the class and from the sponsor's description, not from data on the compound. In primates, a 2026 study of a different oral dual MC3R and MC4R agonist found that adding MC3R activation produced greater weight loss than MC4R agonism alone. That is a finding about the receptor system in monkeys, not about bivamelagon. |
| Human studies cited | 2 | 4 |
| Legal status, US | FDA-approved, prescription only | Investigational, not approved |
Frequently asked questions
What is the difference between Setmelanotide and Bivamelagon?
Setmelanotide: An FDA-approved MC4R agonist for rare genetic forms of obesity driven by defects in the melanocortin pathway. Bivamelagon: An oral MC4R agonist being developed as a tablet counterpart to injected setmelanotide. A 28 person phase 2 in hypothalamic obesity completed in February 2026 with no results posted, and there is no peer reviewed publication on the compound at all.
Which has stronger research evidence, Setmelanotide or Bivamelagon?
This database does not grade compounds. It counts what was run in people: 2 of the 3 studies cited on the Setmelanotide profile were human work, against 4 of 5 for Bivamelagon. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Setmelanotide and Bivamelagon FDA-approved?
Setmelanotide: FDA-approved (Imcivree) for specific genetic obesity indications. Bivamelagon: Not FDA approved. Investigational; phase 2 complete in hypothalamic obesity with no results posted, open label extension enrolling (September 2026)..
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.